GenScript ProBio, a US-based contract development and manufacturing organization specializing in biologics, and Bio Immunitas, a UK-based pharmaceutical company, announced a joint collaboration on Feb. 8, 2023. The aim of this partnership is to develop and fast track manufacturing of a novel therapeutic platform for Bio Immunitas’ novel human recombinant protein (hRPP) platform.
According to a company press release, GenScript will provide investigational new drug-enabling chemicals, manufacturing, and controls services for Bio Immunitas. These are intended to accelerate the preclinical development of two recombinant protein products that will use Bio Immunitas’ hRPP platform.